Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) Other Operating Expenses (2021 - 2024)

GeneDx Holdings has reported Other Operating Expenses over the past 4 years, most recently at $2.6 million for Q4 2024.

  • Quarterly Other Operating Expenses fell 20.59% to $2.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Sep 2025, up 285.59% year-over-year, with the annual reading at -$2.0 million for FY2023, 69.0% up from the prior year.
  • Other Operating Expenses was $2.6 million for Q4 2024 at GeneDx Holdings, up from -$774000.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $13.0 million in Q2 2021 and troughed at -$2.8 million in Q3 2023.
  • The 4-year median for Other Operating Expenses is -$874000.0 (2024), against an average of $705080.0.
  • The largest YoY upside for Other Operating Expenses was 306.38% in 2023 against a maximum downside of 64.64% in 2023.
  • A 4-year view of Other Operating Expenses shows it stood at $13.0 million in 2021, then plummeted by 112.3% to -$1.6 million in 2022, then soared by 306.38% to $3.3 million in 2023, then dropped by 20.59% to $2.6 million in 2024.
  • Per Business Quant, the three most recent readings for WGS's Other Operating Expenses are $2.6 million (Q4 2024), -$774000.0 (Q3 2024), and -$874000.0 (Q2 2024).